Business
OWC Pharmaceutical Research Takes Further Actions to Protect its Intellectual Property
OWC Pharmaceutical Research Takes Further Actions to Protect its Intellectual Property.
About this update from Owc Pharmaceutical Research Corp
[{"type":"text","content":"\n\n\n\nOWC Pharmaceutical Research Takes Further Actions to Protect its Intellectual Property\n\n\n\n\n\nOWC Pharmaceutical Research Takes Further Actions to Protect its Intellectual Property\nActions include the filing of a patent application with the European Union Patent and Trademark Office for its active cannabis based topical cream\nPR Newswire\nPETACH TIKVA, Israel, July 10, 2017\n\n\n\nPETACH TIKVA, Israel, July 10, 2017 /PRNewswire/ --\n\nOWC Pharmaceutical Research Corp. (OTCQB: OWCP) today announced that its wholly-owned, Israel-based subsidiary, One World Cannabis Ltd. (OWC), has filed a patent application with the European Union Patent and Trademark Office for its active cannabinoid-based psoriasis topical cream. (The patent application number is EP 17178303.8)\n\n     (Logo: http://mma.prnewswire.com/media/458036/OWC_Logo.jpg )\n\n\nThis action by OWC is a key step in the Company's continuing program to fully protect its intellectual property (\"IP\"). OWC's strategy in seeking to fully protect its IP, including the filing of this European patent application will enable the Company to accelerate its ongoing discussions and negotiations regarding scientific, medical and commercial collaboration.\n\nCommenting on the filing of the patent application, Mr. Mordechai Bignitz, Chairman and CEO of OWC Pharmaceutical Research, stated, \"Our primary short-term objective is to introduce our topical cream for skin conditions including, most importantly, psoriasis to the market. Our necessity to fully protect our intellectual property limited our ability to provide potential customers and partners with the required data for their due diligence and review. Our proprietary data includes specifics regarding the formulation of the topical cream, consisting of cannabinoids and other compounds that facilitate the efficient delivery of the cream to infected areas. The filing of this European patent application also enables us to fully discuss with potential customers and partners the requirements for manufacturing the cream in accordance with national and local regulations. It also enables us to provide potential customers and partners with the manufacturing requirements, based on the highest-level of international standards and protocols, and includes specifics regarding the manufacturing process ...